Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company specializing in immunotherapies for KRAS-driven cancers, has announced a definitive securities purchase agreement for a registered direct offering expected to yield approximately $15 million in gross proceeds. The offering, which includes 4,380,313 shares of common stock, is anticipated to close on or about July 6, 2026, subject to customary closing conditions.

Elicio Therapeutics is focused on developing next-generation immunotherapies to treat cancers driven by mutations in the KRAS gene, a significant factor in various malignancies. The company's lead product candidate, ELI-002, is an investigational AMP cancer immunotherapy designed to target the most common KRAS mutations found in approximately 25% of all solid tumors. ELI-002 comprises AMP-modified mutant KRAS peptide antigens and an adjuvant, ELI-004, which is intended to enhance the immune response against cancer cells. The company aims to leverage its proprietary AMP technology to improve the education and activation of cancer-specific T cells, potentially offering a more effective treatment option compared to traditional immunotherapy strategies.

The proceeds from this offering will primarily support the planned Phase 1 clinical development of ELI-002 7P in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as contribute to Elicio's broader pipeline and platform initiatives. The company has refined its Phase 3 development strategy based on recent clinical findings, focusing on patients with lower residual disease burden and extended treatment durations. Elicio's approach to off-the-shelf immunotherapy aims to provide rapid availability and lower costs, which could be particularly advantageous in neo-adjuvant settings and for high-risk patients.

The biotechnology sector is currently experiencing a surge in interest, particularly in the development of innovative cancer therapies. With the increasing prevalence of KRAS mutations in various cancers, Elicio's focus on this specific target aligns with broader industry trends toward personalized and effective treatment options. As the company progresses through its clinical trials, the outcomes will be closely monitored by investors and industry stakeholders, particularly given the competitive landscape of cancer immunotherapy.

In summary, Elicio Therapeutics' recent fundraising initiative positions the company to advance its promising pipeline of immunotherapies targeting KRAS-driven cancers. The successful completion of this offering will not only bolster Elicio's financial resources but also enhance its capability to navigate the complexities of clinical development in a rapidly evolving biotechnology sector. As the market continues to evolve, the implications of Elicio's advancements may contribute to significant shifts in treatment paradigms for KRAS-positive cancers, reflecting the ongoing commitment to innovation in cancer therapeutics.